Please use this identifier to cite or link to this item:
http://repository.li.mahidol.ac.th/dspace/handle/123456789/46441
Title: | Factors associated with colistin-resistant acinetobacter baumannii acquisition among hospitalized patients |
Authors: | Peerayuth Pantuwadeethorn Amornrut Leelaporn Pornpan Koomanachai Faculty of Medicine, Siriraj Hospital, Mahidol University |
Keywords: | Medicine |
Issue Date: | 1-Aug-2018 |
Citation: | Journal of the Medical Association of Thailand. Vol.101, No.8 (2018), 1051-1054 |
Abstract: | © 2018, Medical Association of Thailand. All rights reserved. Background: The emergence of multidrug-resistant Acinetobacter baumannii has led to the re-use of colistin. Colistin-resistant A. baumannii [CRA] was rare but is being reported more often now. Objective: To explore the factors associated with CRA. Materials and Methods: A retrospective case-control study has conducted. The medical records of 20 patients with CRA and 80 patients with colistin-susceptible A. baumannii [CSA] were reviewed. Results: Univariate analysis showed that presence of five co-morbidities, intensive care unit stay, prior use of colistin, duration of colistin use, and some prior antibiotics were associated with CRA (p<0.05). However, using multivariate analysis, prior colistin and meropenem use had adjusted odds ratios [AOR] of 21.04; 95% CI of 3.11 to 142.32 (p = 0.002) and 13.54; 95% CI of 1.15 to 159.64 (p = 0.038), respectively, for CRA. Colistin duration (days) was significantly associated with resistance (AOR 1.22, 95% CI of 1.04 to 1.44, p = 0.013). Conclusion: These results should increase awareness of appropriate colistin administration i.e., the duration of colistin used. |
URI: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85052239914&origin=inward http://repository.li.mahidol.ac.th/dspace/handle/123456789/46441 |
ISSN: | 01252208 |
Appears in Collections: | Scopus 2018 |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.